Skip to main content Accessibility help
×
Home
Hostname: page-component-8bbf57454-jcfbx Total loading time: 0.54 Render date: 2022-01-25T05:33:01.905Z Has data issue: true Feature Flags: { "shouldUseShareProductTool": true, "shouldUseHypothesis": true, "isUnsiloEnabled": true, "metricsAbstractViews": false, "figures": true, "newCiteModal": false, "newCitedByModal": true, "newEcommerce": true, "newUsageEvents": true }

Book contents

39 - Management of neuroendocrine tumours

Published online by Cambridge University Press:  05 November 2015

Andrew Lansdown
Affiliation:
Cardiff University School of Medicine, Cardiff, UK
Aled Rees
Affiliation:
Cardiff University, Cardiff, UK
Louise Hanna
Affiliation:
Velindre Cancer Centre, Velindre Hospital, Cardiff
Tom Crosby
Affiliation:
Velindre Cancer Centre, Velindre Hospital, Cardiff
Fergus Macbeth
Affiliation:
Velindre Cancer Centre, Velindre Hospital, Cardiff
Get access

Summary

Introduction

Neuroendocrine tumours (NETs) constitute a heterogeneous group of neoplasms with significant variation in their mode of presentation and biological behaviour. They arise from neuroendocrine cells, which are widely distributed in the body; the spectrum of tumours that fall under this classification is accordingly diverse. Although tumours can arise within endocrine glands such as the pituitary and the parathyroids, tumours at these sites are typically benign, with limited growth potential, and are traditionally managed by endocrinologists. This chapter therefore focuses largely on NETs arising within the bronchial or gastroenteropancreatic systems, historically termed carcinoid tumours.

Management of these rare tumours is improving due to advances in imaging and to the increased use of multidisciplinary teams in specialist centres (Kaltsas et al., 2004; Ramage et al., 2012). Treatment options are diverse and should be tailored individually, but they may include one or more of surgery, medical therapy (somatostatin analogues, interferon alpha, sunitinib and everolimus), chemotherapy, radionuclide therapy, ablative therapy and embolisation. Current clinical trials are focused on defining the optimal use of existing therapies and exploring novel agents such as angiogenesis and MTOR inhibitors.

Tumour types

NETs are classified according to (1) histological differentiation and grading, and (2) staging, based on primary tumour site.

The WHO 2010 classification (Bosman et al., 2010) is based upon the concept that all NETs have malignant potential and is organised according to grade and stage.

Grading is based upon morphological criteria and the proliferative activity of the tumour, including the mitotic activity and/or Ki-67 labelling index. Well-differentiated tumours are divided into low-grade (G1) and intermediate-grade (G2) categories. All poorly differentiated NETs are classified as high-grade (G3) neuroendocrine carcinomas.

Staging systems in place include the Union for International Cancer Control (UICC) (7th edition) and the European Neuroendocrine Tumor Society (ENETS) staging systems (Rindi et al., 2007).

Incidence and epidemiology

The UK annual disease incidence is estimated at 2–5 cases/100,000 patients, with a slight female predominance. Disease incidence is thought to be increasing overall, possibly due to increased diagnostic awareness (Modlin et al., 2008). Autopsy studies indicate that small, clinically unrecognised NETs are relatively common (up to 10% for pancreatic NETs). There is no definite geographical variation in tumour incidence, although there are reported ethnic differences, with African-Americans having the highest incidence of 6.5 per 100,000 per year (Modlin et al., 2003). The average age at diagnosis is 61 years.

Type
Chapter
Information
Publisher: Cambridge University Press
Print publication year: 2015

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Anderson, M. A., Carpenter, S., Thompson, N. W., et al. (2000). Endoscopic ultrasound is highly accurate and directs management in patients with neuroendocrine tumors of the pancreas. Am. J. Gastroenterol., 95, 2271–2277.CrossRefGoogle ScholarPubMed
Baker, M. S., Knuth, J. L., DeWitt, J., et al. (2008). Pancreatic cystic neuroendocrine tumors: preoperative diagnosis with endoscopic ultrasound and fine-needle immunocytology. J. Gastrointest. Surg., 12, 450–456.CrossRefGoogle ScholarPubMed
Bosman, F. T., Carneiro, F., Hruban, R. H., et al. (2010). WHO Classification of Tumours of the Digestive System. Lyon: IARC.Google Scholar
Caplin, M. E., Pavel, M., Cwikla, J. B., et al. (2014). Lanreotide in metastatic enteropancreatic neuroendocrine tumors. N. Engl. J. Med., 371, 224–233.CrossRefGoogle ScholarPubMed
Chiti, A., Briganti, V., Fanti, S., et al. (2000). Results and potential of somatostatin receptor imaging in gastroenteropancreatic tract tumours. Q. J. Nucl. Med., 44, 42–49.Google ScholarPubMed
Cwikla, J. B., Sankowski, A., Sekecka, N., et al. (2010). Efficacy of radionuclide treatment DOTATATE Y-90 in patients with progressive metastatic gastroenteropancreatic neuroendocrine carcinomas (GEP-NETs): a phase II study. Ann. Oncol., 21, 787–794.CrossRefGoogle ScholarPubMed
Eriksson, B. K., Larsson, E. G., Skogseid, B. M., et al. (1998). Liver embolizations of patients with malignant neuroendocrine gastrointestinal tumors. Cancer, 83, 2293–2301.3.0.CO;2-E>CrossRefGoogle ScholarPubMed
Eriksson, B., Oberg, K. and Stridsberg, M. (2000). Tumor markers in neuroendocrine tumors. Digestion, 62 (Suppl. 1), 33–38.CrossRefGoogle ScholarPubMed
Fink, G., Krelbaum, T., Yellin, A., et al. (2001). Pulmonary carcinoid: presentation, diagnosis, and outcome in 142 cases in Israel and review of 640 cases from the literature. Chest, 119, 1647–1651.CrossRefGoogle ScholarPubMed
Gabriel, M., Decristoforo, C., Kendler, D., et al (2007). 68Ga-DOTA-Tyr3-octreotide PET in neuroendocrine tumors: comparison with somatostatin receptor scintography and CT.J. Nucl. Med., 48, 508–518.CrossRefGoogle Scholar
Kaltsas, G., Korbonits, M., Heintz, E., et al. (2001). Comparison of somatostatin analog and meta-iodobenzylguanidine radionuclides in the diagnosis and localization of neuroendocrine tumors. J. Clin. Endocrinol. Metab., 86, 895–902.CrossRefGoogle ScholarPubMed
Kaltsas, G. A., Besser, G. M. and Grossman, A. B. (2004). The diagnosis and medical management of advanced neuroendocrine tumors. Endocr. Rev., 25, 458–511.CrossRefGoogle ScholarPubMed
King, J., Quinn, R., Glenn, D. M., et al. (2008). Radioembolization with selective internal radiation microspheres for neuroendocrine liver metastases. Cancer, 113, 921–929.CrossRefGoogle ScholarPubMed
Krenning, E. P., Teunissen, J. J., Valkema, R., et al. (2005). Molecular radiotherapy with somatostatin analogs for (neuro-)endocrine tumors. J. Endocrinol. Invest., 28 (Suppl. 11), 146–150.Google ScholarPubMed
Lim, E., Goldstraw, P., Nicholson, A. G., et al. (2008). Proceedings of the IASLC International Workshop on Advances in Pulomnary Neuroendocrine Tumors 2007. J. Thorac. Oncol., 3, 1194–1201.CrossRefGoogle Scholar
Mitry, E., Baudin, E., Ducreux, M., et al. (1999). Treatment of poorly differentiated neuroendocrine tumours with etoposide and cisplatin. Br. J. Cancer, 81, 1351–1355.CrossRefGoogle ScholarPubMed
Modlin, I. M., Lye, K. D. and Kidd, M. (2003). A 5-decade analysis of 13,715 carcinoid tumors. Cancer, 97, 934–959.CrossRefGoogle ScholarPubMed
Modlin, I. M., Oberg, K., Chung, D. C., et al. (2008). Gastroenteropanreatic neuroendocrine tumours. Lancet Oncol., 9, 61–72.CrossRefGoogle ScholarPubMed
Pavel, M., Baudin, E., Couvelard, A., et al. (2012). ENETS consensus guidelines for the management of patients with liver and other distant metastases from neuroendocrine neoplasms of foregut, midgut, hindgut and unknown primary. Neuroendocrinology, 95, 157–176.CrossRefGoogle ScholarPubMed
Plockinger, U., Couvelard, A., Falconi, M., et al. (2008) Consensus guidelines for the management of patients with digestive neuroendocrine tumours: well-differentiated tumour/carcinoma of the appendix and goblet cell carcinoma. Neuroendocrinology, 87, 20–30.CrossRefGoogle ScholarPubMed
Ramage, J. K., Ahmed, A., Ardill, J., et al. (2012). Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours (NETs).Gut, 61, 6–32.CrossRefGoogle ScholarPubMed
Raymond, E., Dahan, L., Raoul, J. L., et al. (2011). Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N. Engl. J. Med., 364, 501–513.CrossRefGoogle ScholarPubMed
Rindi, G., Klöppel, G., Couvelard, A., et al. (2007). TNM staging of midgut and hindgut (neuro) endocrine tumors: a consensus proposal including a grading system. Virchows Archiv., 451(4), 757–762.CrossRefGoogle ScholarPubMed
Rinke, A., Müller, H. H., Schade-Brittinger, C., et al. (2009). PROMID Study Group. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J. Clin. Oncol., 27, 4656–4663.CrossRefGoogle Scholar
Rubin, J., Ajani, J., Schirmer, W., et al. (1999). Octreotide acetate long-acting formulation versus open-label subcutaneous octreotide acetate in malignant carcinoid syndrome. J. Clin. Oncol., 17, 600–606.CrossRefGoogle ScholarPubMed
Schillaci, O., Corleto, V. D., Annibale, B., et al. (1999). Single photon emission computed tomography procedure improves accuracy of somatostatin receptor scintigraphy in gastroenteropancreatic tumours. Ital. J. Gastroenterol. Hepatol., 31 (Suppl. 2), S186–189.Google Scholar
Schillaci, O., Spanu, A., Scopinaro, F., et al. (2003). Somatostatin receptor scintigraphy in liver metastasis detection from gastroenteropancreatic neuroendocrine tumors. J. Nucl. Med., 44, 359–368.Google ScholarPubMed
Srirajaskanthan, R., Toumpanakis, C., Karpathakis, A., et al. (2009). Surgical management and palliative treatment in bronchial neuroendocrine tumours: a clinical study of 45 patients. Lung Cancer, 65, 68–73.CrossRefGoogle ScholarPubMed
Strosberg, J. R., Fine, R. L., Choi, J., et al. (2011). First-line chemotherapy with capecitabine and temozolamide in patients with metastatic pancreatic endocrine carcinomas. Cancer, 117, 268–275.CrossRefGoogle Scholar
Sutton, R., Doran, H. E., Williams, E. M., et al. (2003). Surgery for midgut carcinoid. Endocr. Relat. Cancer, 10, 469–481.CrossRefGoogle ScholarPubMed
Tomassetti, P., Migliori, M., Corinaldesi, R., et al. (2000). Treatment of gastroenteropancreatic neuroendocrine tumours with octreotide LAR.Aliment. Pharmacol. Ther., 14, 557–560.CrossRefGoogle ScholarPubMed
Tomassetti, P., Migliori, M., Simoni, P., et al. (2001). Diagnostic value of plasma chromogranin A in neuroendocrine tumours. Eur. J. Gastroenterol. Hepatol., 13, 55–58.CrossRefGoogle ScholarPubMed
Toumpanakis, C., Garland, J., Marelli, L., et al. (2009). Long-term results of patients with malignant carcionoid syndrome receiving octreotide LAR.Aliment. Pharmacol. Ther., 30, 733–740.CrossRefGoogle Scholar
Treglia, G., Castaldi, P., Rindi, G., et al. (2012). Diagnostic performance of Gallium-68 somatostatin receptor PET and PET/CT in patients with thoracic and gastroenteropancreatic neuroendocrine tumours: a meta-analysis. Endocrine, 42, 80–87.CrossRefGoogle ScholarPubMed
Versari, A., Camellini, L., Carlinfante, G., et al. (2010). Ga-68 DOTATOC PET, endoscopic ultrasonography, and multidetector CT in the diagnosis of duodenopancreatic neuroendocrine tumors: a single-centre retrospective study. Clin. Nucl. Med., 35, 321–328.CrossRefGoogle Scholar
Vinjamuri, S., Gilbert, T. M., Banks, M., et al. (2013). Peptide receptor radionuclide therapy with (90)Y-DOTATATE/(90)Y-DOTATOC in patients with progressive metastatic neuroendocrine tumours: assessment of response, survival and toxicity. Br. J. Cancer, 108, 1440–1448.CrossRefGoogle ScholarPubMed
Wolin, E. M., Hu, K., Hughes, G., et al. (2013). Safety, tolerability, pharmacokinetics, and pharmacodynamics of a long-acting release (LAR) formulation of pasireotide (SOM230) in patients with gastoenteropancreatic neuroendocrine tumours: results from a randomized, multicenter, open-label, phase I study. Cancer Chemother. Pharmacol., 72, 387–395.CrossRefGoogle ScholarPubMed
Yadegarfar, G., Friend, L., Jones, L., et al. (2013). Validation of the EORTC QLQ-GINET21 questionnaire for assessing quality of life of patients with gastrointestinal neuroendocrine tumours. Br. J. Cancer, 108(2), 301–310.CrossRefGoogle ScholarPubMed
Yao, J. C., Shah, M. H., Ito, T., et al. (2011). Everolimus for advanced pancreatic neuroendocrine tumours. N. Engl. J. Med., 364, 514–523.CrossRefGoogle Scholar
Zikusoka, M. N., Kidd, M., Eick, G., et al. (2005). The molecular genetics of gastroenteropancreatic neuroendocrine tumors. Cancer, 104, 2292–2309.CrossRefGoogle ScholarPubMed

Send book to Kindle

To send this book to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about sending to your Kindle.

Note you can select to send to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be sent to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Send book to Dropbox

To send content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about sending content to Dropbox.

Available formats
×

Send book to Google Drive

To send content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about sending content to Google Drive.

Available formats
×